Are you saying that Boceprevir ought not to be in the same slot as ITMN-191? There’s no doubt that 191’s data disclosed to date are superior to Boceprevir’s, but IMO this is offset by the fact that Boceprevir is much further along in development. Comments?
Market Data 
Markets 
AI
